Development of a RiskScore model related to cancer-associated fibroblasts for assessing patient prognosis and drug sensitivity in lung adenocarcinoma
Authors:
- Wan LiWLWan Li
- Tianxu GuiTGTianxu Gui
- Yaqin HouYHYaqin Hou
Open Access
- 1 December 2025
- journal article
- Published by KEAI Publishing in Letters in Drug Design & Discovery
- Vol. 22 (12)
Abstract
No abstract availableThis publication has 66 references indexed in Scilit:
- GOT2 Elevation Mediated by YY1 Promotes the Tumorigenesis and Immune Escape of Lung AdenocarcinomaJournal of Biochemical and Molecular Toxicology, 2025
- A Disintegrin and Metalloproteinase 10 Regulates Ephrin B2–Mediated Endothelial Cell Sprouting and Ischemic RetinopathyThe American Journal of Pathology, 2025
- A useful mTORC1 signaling-related RiskScore model for the personalized treatment of osteosarcoma patients by using the bulk RNA-seq analysisDiscover Oncology, 2024
- FHL2 expression by cancer‐associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinomaInternational Journal of Cancer, 2024
- Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platformiMeta, 2024
- FSTL3 is associated with prognosis and immune cell infiltration in lung adenocarcinomaJournal of Cancer Research and Clinical Oncology, 2024
- A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcomaCancer Medicine, 2021
- A gene expression-based immune signature for lung adenocarcinoma prognosisCancer Immunology, Immunotherapy, 2020
- Cancer‐associated fibroblasts: Secretions, interactions, and therapyJournal of Cellular Biochemistry, 2018
- Ephrin‐B2 overexpression predicts for poor prognosis and response to therapy in solid tumorsMolecular Carcinogenesis, 2016